Section Arrow
Quote
CRNX.NASDAQ
- Crinetics Pharmaceuticals
Quotes are at least 15-min delayed:2026/04/29 08:26 EDT
Pre Market
Last
 36.3
-1.85 (-4.85%)
Bid
36.5
Ask
40
High 38.5 
Low 35.15 
Volume 46 
Regular Hours (Closed)
Last
 38.15
-0.47 (-1.22%)
Day High 
40 
Prev. Close
38.62 
1-M High
41.325 
Volume 
1.68M 
Bid
36.5
Ask
40
Day Low
37.49 
Open
39.41 
1-M Low
33.1 
Market Cap 
4.04B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 39.33 
20-SMA 38.57 
50-SMA 38.95 
52-W High 57.99 
52-W Low 25.83 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.95/-4.98
Enterprise Value
4.09B
Balance Sheet
Book Value Per Share
9.48
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
7.70M
Operating Revenue Per Share
0.05
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CLDICalidi Biotherapeutics0.224-0.0135-5.68%0.66PE
Pre Market 0.203 -0.021 -9.38%
ERASErasca9.9-9.25-48.30%-- 
Pre Market 9.8079 -0.0921 -0.93%
CMPXCompass Therapeutics1.84+0.05+2.79%-- 
Pre Market 1.8804 +0.0404 +2.20%
ASBPAspire Biopharma Holdings Inc.0.2087-0.0363-14.82%-- 
Pre Market 0.2181 +0.0094 +4.50%
SNGXSoligenix Inc.0.4209-0.9941-70.25%-- 
Pre Market 0.41 -0.0109 -2.59%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.